Exécution de notre outil de synthèse sur un nouvel article
Vérifiez l’article ci-dessous, puis lancez sa synthèse.
Implication of gut microbiome in immunotherapy for colorectal cancer
Evangelos Koustas (National and Kapodistrian University of Athens), Eleni-Myrto Trifylli (National and Kapodistrian University of Athens), Panagiotis Sarantis (National and Kapodistrian University of Athens), Nikolaos Papadopoulos, Georgios Aloizos, Ariadne Tsagarakis (Beth Israel Deaconess Medical Center), Christos Damaskos (National and Kapodistrian University of Athens), Nikolaos Garmpis (National and Kapodistrian University of Athens, Laiko General Hospital of Athens), Anna Garmpi (National and Kapodistrian University of Athens), Athanasios G. Papavassiliou (National and Kapodistrian University of Athens), Michalis V. Karamouzis (National and Kapodistrian University of Athens)
Résumé : Colorectal cancer (CRC) constitutes the third most frequently reported malignancy in the male population and the second most common in women in the last two decades. Colon carcinogenesis is a complex, multifactorial event, resulting from genetic and epigenetic aberrations, the impact of environmental factors, as well as the disturbance of the gut microbial ecosystem. The relationship between the intestinal microbiome and carcinogenesis was relatively undervalued in the last decade. However, its remarkable effect on metabolic and immune functions on the host has been in the spotlight as of recent years. There is a strong relationship between gut microbiome dysbiosis, bowel pathogenicity and responsiveness to anti-cancer treatment; including immunotherapy. Modifications of bacteriome consistency are closely associated with the immunologic response to immunotherapeutic agents. This condition that implies the necessity of gut microbiome manipulation. Thus, creatingan optimal response for CRC patients to immunotherapeutic agents. In this paper, we will review the current literature observing how gut microbiota influence the response of immunotherapy on CRC patients.